ASIS for GAMMAGARD in Primary Immunodeficiency

NCT02123615 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency

Interventions

DRUG: Gadolinium For abdomen
DRUG: Gadolinium For abdomen
DRUG: Gadolinium For abdomen
DRUG: Gadolinium For lower back
DRUG: Gadolinium For lower back
DRUG: Gadolinium For lower back
DRUG: Efficacy of Gammagard subcutaneously at Week 12
DRUG: Efficacy of Gammagard subcutaneously at Week 12
DRUG: Efficacy of Gammagard subcutaneously at Week 12
DRUG: Efficacy of Gammagard subcutaneously at Week 12
DRUG: Efficacy of Gammagard subcutaneously at Week 12
DRUG: Efficacy of Gammagard subcutaneously at Week 12
DRUG: Efficacy of Gammagard subcutaneously at Week 12
DRUG: Efficacy of Gammagard subcutaneously at Week 12
DRUG: Efficacy of Gammagard subcutaneously at Week 24
DRUG: Efficacy of Gammagard subcutaneously at Week 24
DRUG: Efficacy of Gammagard subcutaneously at Week 24
DRUG: Efficacy of Gammagard subcutaneously at Week 24
DRUG: Efficacy of Gammagard subcutaneously at Week 24
DRUG: Efficacy of Gammagard subcutaneously at Week 24

Sponsor

ASIS Corporation